There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
“There is a significant probability of a large scale and lethal modern day pandemic
occurring in our lifetimes.”
~Bill Gates
Since the great plague and cholera epidemics that occurred before the twentieth century,
there have been a number of other pandemics starting with the Spanish Flu in 1918.
In December, 2019, a new coronavirus, now recognized as COVID-19, began to cause respiratory
illness in Wuhan, China. The epidemic began in a fish market and is most similar to
snake, pangolin, horseshoe crab, and bat corona viruses. In humans it is spread by
respiratory droplets. It can remain alive on plastic surfaces for over 72 hours. It
is spread by respiratory droplets. At the Shattuck lecture in Boston in 2018. Bill
Gates called for a “clear road map for a comprehensive pandemic preparedness and response
system (1).”Since the great plague and cholera epidemics that occurred before the
twentieth century, there have been a number of other pandemics starting with the Spanish
Flu in 1918. In December, 2019, a new coronavirus, now recognized as COVID-19, began
to cause respiratory illness in Wuhan, China. The epidemic began in a fish market
and is most similar to snake, pangolin, horseshoe crab, and bat corona viruses. In
humans it is spread by respiratory droplets. It can remain alive on plastic surfaces
for over 72 hours. It is spread by respiratory droplets. At the Shattuck lecture in
Boston in 2018. Bill Gates called for a “clear road map for a comprehensive pandemic
preparedness and response system (1).”
COVID-19 presents with nasal secretions, cough, dyspnea, fever, myalgia and occasionally
diarrhea. Around 15% may go on to develop acute respiratory distress syndrome for
5 days, but may last up to 14 days. Viral shedding may last up to 37 days. Over 95%
of hospitalized patients have abnormal chest computed tomography (2). On CT, ground
glass opacities with a reticular pattern, a subplural line, fibrotic streaks and an
air bronchogram were the most common signs (3). These findings allowed COVID-19 pneumonia
to be separated from classical viral pneumonia. From the laboratory point of view
lymphocytopenia, elevated C-reactive protein, elevated interleukin-6, elevated lactic
dehydrogenase, hypoalbuminemia, a decreased CD8 count increased ferritin and decreased
procalcitonin (4). In addition, very high angiotensin II levels were present. Highly
elevated d-dimer levels are associated with mortality for people on ventilators.
Besides acute respiratory distress syndrome severely ill patients develop myocardial
damage and this is associated with increased mortality. Kidney and liver disease also
occur. COVID-19 enters the central nervous system and increases inflammatory cytokines
which can be expected to lead to delirium. Older people also have an increase in delirium
and do not always have an increase in fever.
The prevalence of COVID-19 in the community is uncertain as it appears a number of
persons may not show symptoms. It would appear that the mortality may be as low as
0.6% (5). It is clear that older persons are at a much higher risk of mortality (about
15%) than younger persons (5). Persons with comorbidity are at an increased risk.
It is suggested that the FRAIL screen is used to detect persons at increased risk
(6, 7, 8). Persons with hypertension and diabetes mellitus are at increased risk possibly
due to alterations in the angiotensin converting enzyme 2 (ACE 2) receptor produced
by ACE 1 inhibitors.
Primary prevention especially for older persons with comorbidity is social distancing
and where possible social isolation. For older persons the problem with social isolation
is loneliness (9). Loneliness leads to depression, cognitive dysfunction, disability,
cardiovascular disease and increased mortality. Obviously, prevention also requires
regular hand washing and cleaning of surfaces. Wearing a mask does not provide protection
for the individual. Finally, the first vaccine has just started testing. If it or
other vaccines under development mount an adequate antibody response there will be
a need to try to rapidly bring it to the general public. It is important to recognize
that some persons, like “Typhoid Mary” who spread typhoid fever in the 1910s, may
be asymptomatic. Thus, distance must be kept from everybody.
At present, while there are no established drugs to treat COVID-19, some are showing
promise. Chloroquine phosphate, an anti-malarial, has been shown to be useful in treating
COVID-19 pneumonia (10). Remdesivir, an antiviral drug developed to treat Ebola, has
been suggested to have positive effects in COVID-19 infected patients with severe
respiratory disease (11). These patients developed gastrointestinal symptoms and elevated
liver function tests. Some patients with severe COVID-19 disease develop cytokine
storm and this may be prevented with toclizumab. Passive infusion of polyclonal plasma
antibodies from persons who have had COVID-19 infection has been suggested and monoclonal
antibodies to COVID-19 are under development (12). Finally, COVID-19 binds to the
soluble portion of the ACE-2 receptor and this seems essential for the virus to enter
cells. The possibility of a monoclonal antibody to the soluble portion of the ACE-2
receptor is under consideration. It is uncertain whether stopping the use of ACE 1
inhibitors which increase ACE-2 receptors should be undertaken. However, this may
explain the increased virulence of COVID-19 in persons with hypertension and diabetes
mellitus. COVID-19 infected patients may do worse if taking ibuprofen, so it is recommended
that patients take acetaminophen or paracetamol for fever and pain.
In conclusion, COVID-19 represents a major threat to older adults. This is particularly
true in older persons with frailty and co-morbidity. Other factors that appear to
play a role in the increased severity in older persons are the decline in immune function
and alterations in the ACE 2 receptor. There is need for rapid development of a COVID-19
vaccine and its deployment among the population. In the meantime, social distancing,
careful hand washing and using antiseptic wipes to clean surfaces and door handles
before touching them represent the appropriate preventive measures. During the pandemic
it is especially important to isolate older persons in nursing homes and to provide
support when nursing home staff need to be quarantined. With good population health
approaches, it is expected that the COVID-19 pandemic will be controlled in a relatively
short time period.
The outbreak of the 2019-nCoV infection began in December 2019 in Wuhan, Hubei province, and rapidly spread to many provinces in China as well as other countries. Here we report the epidemiological, clinical, laboratory, and radiological characteristics, as well as potential biomarkers for predicting disease severity in 2019-nCoV-infected patients in Shenzhen, China. All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS). The most common laboratory abnormalities were hypoalbuminemia, lymphopenia, decreased percentage of lymphocytes (LYM) and neutrophils (NEU), elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH), and decreased CD8 count. The viral load of 2019-nCoV detected from patient respiratory tracts was positively linked to lung disease severity. ALB, LYM, LYM (%), LDH, NEU (%), and CRP were highly correlated to the acute lung injury. Age, viral load, lung injury score, and blood biochemistry indexes, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%), may be predictors of disease severity. Moreover, the Angiotensin II level in the plasma sample from 2019-nCoV infected patients was markedly elevated and linearly associated to viral load and lung injury. Our results suggest a number of potential diagnosis biomarkers and angiotensin receptor blocker (ARB) drugs for potential repurposing treatment of 2019-nCoV infection. Electronic Supplementary Material Supplementary material is available for this article at 10.1007/s11427-020-1643-8 and is accessible for authorized users.
[1
]GRID grid.262962.b, ISNI 0000 0004 1936 9342, School of Social Work, , Saint Louis University, ; St. Louis, Missouri USA
[2
]GRID grid.414282.9, ISNI 0000 0004 0639 4960, Gérontopôle, Department of Geriatrics, CHU Toulouse, , Purpan University Hospital, ; Toulouse, France
[3
]GRID grid.262962.b, ISNI 0000 0004 1936 9342, Division of Geriatric Medicine, , Saint Louis University School of Medicine, ; 1402 S. Grand Blvd., St. Louis, MO M238 63104 USA
This article is made available via the PMC Open Access Subset for unrestricted research
re-use and secondary analysis in any form or by any means with acknowledgement of
the original source. These permissions are granted for the duration of the World Health
Organization (WHO) declaration of COVID-19 as a global pandemic.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.